Long COVID’s brain toll
New research underscores persistent neurological and psychiatric effects from long COVID—estimates suggest 80–400 million people worldwide still experience lingering symptoms like cognitive issues and mood disorders (news-medical.net). The findings keep post‑infection monitoring and cognitive rehab on the agenda for healthcare planning even three years after the pandemic peak (news-medical.net).
The paper behind the coverage is a multi‑author primer in Nature Reviews Disease Primers (Jo Ellen Wilson et al.; DOI 10.1038/s41572-025-00674-7) that specifically maps neurological and psychological manifestations linked to SARS‑CoV‑2 infection. (nature.com) The authors estimate incidence ranges of roughly 5–20% for post‑COVID conditions in community cases and report rates as high as ~50% among patients who were hospitalized, with the caveat that post‑intensive‑care syndromes can overlap. (nature.com) The review enumerates common neuropsychiatric presentations — including memory deficits, executive‑function impairment, anxiety, depression, recurring headaches, sleep disturbance, peripheral neuropathies, anosmia/ageusia and dizziness often linked to dysautonomia and post‑exertional malaise. (nature.com) Authors list multiple putative mechanisms under active study: SARS‑CoV‑2 viral persistence, herpesvirus reactivation, gut microbiota dysbiosis, autoantibody‑driven processes, endothelial and clotting abnormalities, and chronic immune activation. (nature.com) Risk factors highlighted in the primer include female sex, older age, lower socioeconomic status, occupations such as healthcare work or teaching, more severe acute COVID‑19, pre‑existing comorbidities and lack of vaccination against SARS‑CoV‑2. (nature.com) The paper notes there are currently no validated biomarkers for diagnosis (clinical history and exclusion of other causes remain central) and it flags psychological therapies, physiotherapy and non‑invasive brain stimulation among the most promising non‑pharmacological treatment avenues cited for neuropsychiatric long‑COVID care. (nature.com)
